Maxim Group analyst Anthony Vendetti maintained a Buy rating on Nuwellis (NUWE – Research Report) yesterday. The company’s shares opened today at $0.50.
According to TipRanks, Vendetti is an analyst with an average return of -2.6% and a 32.39% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Sensus Healthcare, cbdMD, and Biolase.
Currently, the analyst consensus on Nuwellis is a Moderate Buy with an average price target of $9.00.
See today’s best-performing stocks on TipRanks >>
Based on Nuwellis’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.41 million and a GAAP net loss of $3.37 million. In comparison, last year the company earned a revenue of $2.07 million and had a GAAP net loss of $3.87 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nuwellis (NUWE) Company Description:
CHF Solutions, Inc. is a medical device company, which engages in the provision of products for the treatment of fluid overload. Its product include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.
Read More on NUWE:
- Nuwellis announces results from clinical data anaylses of AVOID-HF trial
- Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference
- Nuwellis reports Q4 EPS ($2.24), consensus ($1.39)
- Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
- Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
